BUDAPEST, June 19 (Reuters) - Hungarian drug manufacturer Gedeon Richter GDRB.BU said on Friday it had signed a deal with U.S.-based KV Pharmaceutical Company for licensing rights to some of KV’s technologies and products.
The agreement gives Richter manufacturing and distribution rights in the European Union, the company said in a filing with the Budapest Stock Exchange. Financial details were not disclosed.
“It allows us to enhance our existing female healthcare portfolio, not only in our traditional markets, but in all EU member states,” Richter CEO Erik Bogsch said.
Reporting by Krisztina Than; editing by John Stonestreet